Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Best Supportive Care (Maintenance) Clear all
Completed Phase 3 Interventional Results available

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Oral Azacitidine, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
60
States / cities
Phoenix, Arizona • Burbank, California • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

NCT02027428
View directory record Official record
Conditions
Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions
Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
91
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

NCT00102804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
6
States / cities
Minneapolis, Minnesota • Portsmouth, New Hampshire • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2014 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Not applicable Interventional

A Primary Palliative Care Intervention for Patients With Advanced Cancer

NCT02712229
View directory record Official record
Conditions
Advanced Cancer
Interventions
CONNECT
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Primary Care Clinical Excellence Incentive Study

NCT04237883
View directory record Official record
Conditions
Behavioral Economics, Primary Health Care, Health Maintenance, Diabetes, Colorectal Cancer Screening, Cervical Cancer Screening, Chlamydia Screening, HPV Screening
Interventions
Standard communication email, Social comparison Intervention, Leadership Training
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brentwood, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 17, 2026, 6:48 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Pittsburgh Study Early Childhood

NCT05444205
View directory record Official record
Conditions
Child Development, Child Language, Child Behavior Problem, Parenting, Parent Child Abuse
Interventions
Text4Baby or Bright by Text Referral, Nurture Program Warm Referral, Video Interaction Project, Family Check-UP, Smart Beginnings, Healthy Families America Warm Referral, Family Center Warm Referral
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 6 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2031
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

NCT04102020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Venetoclax, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Mobile, Alabama • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Enrolling by invitation Not applicable Interventional

Experimental Trial of an Employment-Based Housing Program for Adults at Risk of Homelessness

NCT07470372
View directory record Official record
Conditions
Emergency Department Visits, Housing Stability, Employment, Sleep Quality, Health-Related Quality-of-Life
Interventions
Employment-Based Housing, Vocational Services, Resources
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Active, not recruiting Not applicable Interventional

Centralized Prescribing for Statins

NCT05537064
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Non-visit Based Intervention, Visit-Based Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
1,950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Child Care Staff Weight Management Program

NCT05656807
View directory record Official record
Conditions
Obesity
Interventions
Go NAPSACC Enhanced, Go NAPSACC
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
2 Years and older
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

The BEST Trial: Biomarkers for Evaluating Spine Treatments

NCT05396014
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Enhanced Self-Care (ESC), Acceptance and Commitment Therapy (ACT), Evidence-Based Exercise and Manual Therapy (EBEM), Duloxetine
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Redwood City, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 17, 2026, 6:48 AM EDT
Recruiting Not applicable Interventional

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

NCT07105007
View directory record Official record
Conditions
HIV, Heart Failure
Interventions
Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Active, not recruiting Not applicable Interventional

Enhancing Mental and Physical Health of Women Veterans

NCT05050266
View directory record Official record
Conditions
Cardiovascular Diseases, Overweight, Obesity, Smoking, Hypertension, Cholesterol, Diabetes Mellitus, Prediabetic State, Pregnancy, Depression, Postpartum, Prevention, Implementation Science, Quality Improvement, Virtual Care
Interventions
EBQI, REP
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient-Centered Dementia Care Practice Coaching Intervention

NCT06249204
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Coaching Group
Behavioral
Lead sponsor
Alzheimer's Disease and Related Disorders Association, Inc
Other
Eligibility
18 Years to 100 Years
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

NCT02409342
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
9
States / cities
La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Piloting +Connection is Medicine / The Healing Spirits Program

NCT05424679
View directory record Official record
Conditions
Mental Health Issue, Depressive Symptoms, Anxiety
Interventions
Safety Planning Intervention, Caring Contacts
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
11 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Chinle, Arizona • Tuba City, Arizona • Whiteriver, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

NCT00676507
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions
Lucanix™, Placebo Comparator
Biological · Other
Lead sponsor
NovaRx Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
53
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 17, 2026, 6:48 AM EDT
Recruiting Phase 3 Interventional

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

NCT06066502
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
Precision ventilation, Guided usual care ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

NCT04557735
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Best Supportive Care
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

NCT02367794
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
57
States / cities
Chandler, Arizona • Springdale, Arkansas • Bellflower, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 17, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02367781
View directory record Official record
Conditions
Carcinoma, Non-Squamous Non-Small Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
57
States / cities
Springdale, Arkansas • Oakland, California • Roseville, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 17, 2026, 6:48 AM EDT
Recruiting Not applicable Interventional

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NCT06855706
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
Behavioral · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 17, 2026, 6:48 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

NCT03641287
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Transitional Cell Carcinoma
Interventions
Exercise Counseling, Aerobic Exercise, Physiological Support, Quality-of-Life Assessment, Questionnaire Administration, Best Practice
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 17, 2026, 6:48 AM EDT